Eye-drop maker recalls CVS, Target, Walmart-branded products
By Eleanor Laise
Recall triggered by insanitary conditions found by FDA investigators
The manufacturer of eye drops sold under CVS Health Corp. (CVS), Target Corp. (TGT), Rite Aid Corp. (RADCQ), Walmart Inc. (WMT) and other brands has recalled 27 products that were the subject of recent U.S. Food and Drug Administration warnings about potential contamination.
Kilitch Healthcare India Ltd., a pharmaceutical company based in Mumbai, is voluntarily recalling the products labeled with the brands of the major retailers as well as Cardinal Health Inc.'s (CAH) Rugby and Leader labels, according to an announcement posted Wednesday on the FDA's site.
The products are being recalled due to potential safety concerns after FDA investigators found insanitary conditions, the statement said. The recall includes all lots with expiration dates ranging from November 2023 to September 2025. The products were distributed nationwide to retailers and wholesalers and via the product distributor Velocity Pharma LLC.
The FDA warned consumers in late October not to buy or use the products, saying they pose a risk of eye infections that could cause partial vision loss or blindness. The retailers pulled affected products from their shelves.
Kilitch has not received any reports of adverse events related to the recall, according to the statement posted Wednesday.
The recall comes on the heels of an FDA warning to Amazon.com Inc. (AMZN) about the sale of unapproved eye drops marketed for treatment of redness, pink eye and other conditions. The agency warned CVS and Walgreens Boots Alliance Inc. (WBA) about similar issues in September.
A string of eye-product safety issues has emerged this year amid increased federal scrutiny of eye-drop manufacturing. Several other eye-drop brands were also the subject of recalls earlier this year due to concerns about dangerous infections.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-16-23 1154ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks